ReviewClinical cardiology2018
Acromegalic cardiomyopathy: Epidemiology, diagnosis, and management.
Review in Clinical cardiology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 51 citations in OpenAlex.
- Socioeconomic factors associated with post-operative biochemical remission in acromegaly.Journal of neuro-oncology · 2026Article
- Acromegalic cardiomyopathy with end-stage heart failure treated with left ventricular assist device: a case report.Journal of medical case reports · 2026Article
- Review
- Cardiomyopathy in women with acromegaly: clinical characteristics and associated factors in a Colombian multicenter registry.Frontiers in endocrinology · 2026Article
- Aortic Valve Annular Features in Acromegaly-A Detailed Three-Dimensional Speckle-Tracking Echocardiographic Analysis from the MAGYAR-Path Study.Journal of clinical medicine · 2025Article
- Anesthetic Management for Pituitary Tumor Resection in a Patient With Acromegalic Cardiomyopathy: A Case Report.Clinical case reports · 2025Article
- Cardiomyopathies of endocrine origin: A state-of-the-art review.World journal of cardiology · 2025Review
- Acromegaly and Cardiovascular Disease: Associated Cardiovascular Risk Factors, Cardiovascular Prognosis, and Therapeutic Impact.Journal of clinical medicine · 2025Review
- Echocardiographic Findings in Cardiomyopathy Due to Acromegaly.Biomedicines · 2025Article
- Regression of biventricular hypertrophy in acromegalic cardiomyopathy following management of excessive growth hormone secretion.Oxford medical case reports · 2024Article
- Management of Diabetes Mellitus in Acromegaly and Cushing's Disease with Focus on Pasireotide Therapy: A Narrative Review.Diabetes, metabolic syndrome and obesity : targets and therapy · 2024Review
- How to position sodium-glucose co-transporter 2 inhibitors in the management of diabetes in acromegaly patients.Endocrine · 2023Review
- Cardiovascular Effects of Excess Growth Hormone: How Real is the Threat?Reviews in cardiovascular medicine · 2023Review
- Role of cardiovascular magnetic resonance in the clinical evaluation of left ventricular hypertrophy: a 360° panorama.The international journal of cardiovascular imaging · 2023Review
- Article
- [Cardiovascular complications associated with acromegaly. A state-of-the-art].Archivos de cardiologia de Mexico · 2022Article
- Increased insulin-like growth factor 1 concentrations in a retrospective population of non-diabetic cats diagnosed with hypertrophic cardiomyopathy.Journal of feline medicine and surgery · 2021Article
- Association between biochemical control and comorbidities in patients with acromegaly: an Italian longitudinal retrospective chart review study.Journal of endocrinological investigation · 2020Article
- Italian Association of Clinical Endocrinologists (AME) and Italian AACE Chapter Position Statement for Clinical Practice: Acromegaly - Part 1: Diagnostic and Clinical Issues.Endocrine, metabolic & immune disorders drug targets · 2020Review
- Cardiac resynchronization therapy improves heart failure in one patient with acromegaly-induced cardiomyopathy: a case report.Journal of medical case reports · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Acromegalic cardiomyopathy is the leading cause of morbidity and all-cause mortality in patients with acromegaly. Though acromegaly is a rare condition, the associated derangements are vast and severe. Stemming from an increase in circulating growth hormone (GH) and insulin-like growth factor-1 levels (IGF-1), acromegalic cardiomyopathy results in pathological changes in myocyte growth and structure, cardiac contractility, and vascular function. These molecular changes manifest commonly as biventricular hypertrophy, diastolic and systolic dysfunction, and valvular regurgitation. Early recognition of the condition is paramount, though the insidious progression of the disease commonly results in a late diagnosis. Biochemical testing, based on IGF-1 measurements, is the gold standard of diagnosis. Management should be centered on normalizing serum levels of both IGF-1 and GH. Transsphenoidal resection remains the most cost-effective and permanent treatment for acromegaly, though medical therapy possesses benefit for those who are not surgical candidates. Ultimately, achieving control of hormone levels results in a severe reduction in mortality rate, underscoring the importance of early recognition and treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.